Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
non-structural protein
|
| gptkbp:activeSiteResidue |
gptkb:His41
Cys145 |
| gptkbp:alsoKnownAs |
gptkb:3CLpro
main protease |
| gptkbp:biologicalProcess |
gptkb:cysteine_protease
|
| gptkbp:cleavage |
Leu-Gln↓(Ser,Ala,Gly)
|
| gptkbp:EC_number |
3.4.22.69
|
| gptkbp:encodedBy |
ORF1ab
|
| gptkbp:foundIn |
coronaviruses
|
| gptkbp:function |
protease activity
cleavage of viral polyprotein |
| https://www.w3.org/2000/01/rdf-schema#label |
NSP5
|
| gptkbp:inhibitedBy |
gptkb:nirmatrelvir
gptkb:GC376 gptkb:boceprevir |
| gptkbp:length |
306 amino acids (SARS-CoV-2)
|
| gptkbp:locatedOnChromosome |
ORF1ab polyprotein region
|
| gptkbp:PDBEntry |
gptkb:6LU7
|
| gptkbp:presentIn |
gptkb:COVID-19
gptkb:MERS-CoV gptkb:SARS-CoV |
| gptkbp:requires |
viral replication
|
| gptkbp:role |
processing of viral polyproteins pp1a and pp1ab
|
| gptkbp:structure |
homodimer
|
| gptkbp:target |
antiviral drug development
|
| gptkbp:targetOfDrug |
COVID-19 therapeutics
|
| gptkbp:UniProtID |
P0DTD1 (SARS-CoV-2)
|
| gptkbp:bfsParent |
gptkb:rotavirus
|
| gptkbp:bfsLayer |
6
|